Journal of the American Society of Nephrology
Empagliflozin was well tolerated in a kidney disease trial
In both groups, 96% tolerated the full dose; height-adjusted kidney volume grew 10.5% a year with empagliflozin versus 5.1% with placebo.In both groups, 96% tolerated the full dose; height-adjusted kidney volume grew 10.5% a year with empagliflozin versus 5.1% with placebo.
Randomized trial · 50 peopleEmpagliflozin
Who was studied50 adults with autosomal dominant polycystic kidney disease, against placebo
What changedFull-dose treatment was tolerated by 96% in both the empagliflozin and placebo groups
The catchThe safety assessment included only 50 adults
